CD8A and neoplasm: Interestingly, UFL1 can be phosphorylated by AMP-activated protein kinase (AMPK), which leads to the reduction in PD-1 UFMylation and the subsequent destabilization of PD-1, consequently enhancing CD8+ T cell activation and anti-tumor immunity.